MDVN

Medivation, Inc. Press Releases

$109.28
*  
1.97
1.77%
Get MDVN Alerts
*Delayed - data as of Nov. 21, 2014  -  Find a broker to begin trading MDVN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    MDVN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner
11/17/2014 4:10:00 PM - Market Wire


Emera Inc. Sells Its Interest in Northeast Wind
11/17/2014 4:10:00 PM - Business Wire


Dr. David Hung, founder, President and CEO of Medivation, named EY Entrepreneur Of The Year™ 2014 National Overall Award winner
11/17/2014 8:00:00 AM - PR Newswire


David Hung, MD of Medivation Named EY Entrepreneur Of The Year™ 2014 National Life Sciences Award Winner
11/17/2014 8:00:00 AM - PR Newswire


Medivation Reports Third Quarter Financial Results and Provides Corporate Update
11/6/2014 4:10:00 PM - Market Wire
▲4.21 % Price Change since this news event. The Volume Ratio is 3.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Medivation Announces Participation at Upcoming Investor Conference
11/5/2014 4:10:00 PM - Market Wire
▲6.33 % Price Change since this news event. The Volume Ratio is 1.4.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy
10/30/2014 11:00:00 PM - Market Wire
▲6.37 % Price Change since this news event. The Volume Ratio is 1.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Medivation Announces Participation at Upcoming Investor Conference
10/28/2014 4:10:00 PM - Market Wire
▲8.01 % Price Change since this news event. The Volume Ratio is 1.25.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


INSERTING and REPLACING XTANDI™ (Enzalutamide) Capsules Receive Positive CHMP Opinion for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve
10/24/2014 9:06:00 AM - Business Wire
▲7.72 % Price Change since this news event. The Volume Ratio is 0.6.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology
10/23/2014 5:12:00 PM - Market Wire
▲9.94 % Price Change since this news event. The Volume Ratio is 0.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Medivation Announces Third Quarter 2014 Financial Results Teleconference on November 6, 2014
10/23/2014 4:00:00 PM - Market Wire
▲9.94 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


EY Announces leaders from Medivation, MongoDB, Trulia, and zulily inc. recipients of its 2014 Venture Capital Award of Excellence
10/9/2014 2:26:00 PM - PR Newswire
▲15.20 % Price Change since this news event. The Volume Ratio is 0.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Quarterly Changes to the NASDAQ Q-50 Index
9/15/2014 7:05:00 AM - GlobeNewswire


U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
9/10/2014 4:39:00 PM - PR Newswire


U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer
9/10/2014 4:20:00 PM - Market Wire